Supplementary Figure Legend from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

PDF file - 61KB</p

Supplementary Figure 1 from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

PDF file - 69KB, Menadione induces EGFR phosphorylation in A431 cells.</p

Supplementary Figure 3 from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

PDF file - 57KB, Effect of exogenous EGF on EGFR tyrosine kinase inhibition by erlotinib or cetuximab in A431 cells.</p

Supplementary Figure 2 from The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab

PDF file - 55KB, Effects of VK1, VK2, and menadione (VK3) on EGFR phosphorylation in A431 cells.</p

sj-doc-1-tar-10.1177_17534666221135324 – Supplemental material for Interventional pulmonology use of cell-free DNA assay for metastatic non–small cell lung cancer: the UC Davis experience

Supplemental material, sj-doc-1-tar-10.1177_17534666221135324 for Interventional pulmonology use of cell-free DNA assay for metastatic non–small cell lung cancer: the UC Davis experience by Chinh Phan, Forrest Jespersen, Caroline Weipert, Tianhong Li and Ken Y. Yoneda in Therapeutic Advances in Respiratory Disease</p

SBP1 promoter was hypermethylated in human cancer tissues and colon cancer cell lines, which silenced gene expression and was revered by 5-Aza-2′-Deoxycytidine (DAC).

<p>A, SBP1 promoter was highly methylated in human colon cancer tissues. Genomic DNA from adjacent normal (N) and adenocarcinoma (T) tissue was isolated, converted and amplified for human SBP1 promoter using MS-PCR. # indicated different patients. Unmethylated (U) and methylated (M) bands were detected by DNA separation on 2% agarose gels with ethidium bromide. B, Western blotting analysis showed various expression of SBP1 in human colon cancer cell lines; HCT116 cells with stable transfection of SBP1 overexpressing plasmid was used as positive control. C, SBP1 promoter was hypermethylated in HCT116 cells. Genomic DNA from LS174T, HCT116, SW480, Caco-2 and HT-29 colon cancer cells was isolated, converted and amplified via MS-PCR for human SBP1 promoter followed by gel separation of total DNA on 2% agarose gels (U, unmethylated DNA; M, methylated DNA). D, DAC reversed SBP1 promoter methylation in HCT116 cells. DNA from HCT116 cells treated with 30 µM of DAC for 96 h was isolated and separated on 2% agarose gels after conversion and MS-PCR. E, Luciferase assay showed that DAC increased SBP1 promoter luciferase activity of HCT116 cells with transfection of a vector containing the full length promoter of SBP1 and with a treatment of 30 µM DAC or PBS for 72 hours. pGL4 vector and Renilla was co-transfected as controls (* p<0.01, compared to PBS). F, DAC restored SBP1 protein expression in HCT116 cells with DAC treatment for 72 h, analyzed by Western blotting. G. SBP1 mRNA was restored by DAC in HCT116 cells (* p<0.01, compared to PBS). Each experiment was performed at least 3 times.</p

BP1 attenuated colorectal cancer cell growth in NIH-III nude mice.

<p>NIH-III nude mice were injected with HCT116 cells stably expressing SBP1 (pIRES2-SBP1) or vector (pIRES2) control. Four weeks after injection, tumor volume (A) and tumor weight (B) was determined.</p

Isolation of 11,12-<i>seco</i>-Rifamycin W Derivatives Reveals a Cleavage Pattern of the Rifamycin <i>Ansa</i> Chain

This study reported the isolation and characterization of 11 rifamycin congeners including six new ones (1–6) from the agar fermentation extract of Amycolatopsis mediterranei S699. Compounds 1 and 2 are rifamycin glycosides named as rifamycinosides A and B, respectively. Their polyketide skeleton represents a novel cleavage pattern of the rifamycin ansa chain. Compounds 6 and 8 showed potential T3SS inhibitory activity, and 6 induced G2/M phase arrest and caused DNA damage in HCT116 cells

Targeted Discovery and Combinatorial Biosynthesis of Polycyclic Tetramate Macrolactam Combamides A–E

Polycyclic tetramate macrolactams (PoTeMs) are a growing class of natural products with distinct structure and diverse biological activities. By promoter engineering and heterologous expression of the cryptic <i>cbm</i> gene cluster, four new PoTeMs, combamides A–E (<b>1</b>–<b>4</b>), were identified. Additionally, two new derivatives, combamides E (<b>5</b>) and F (<b>6</b>), were generated via combinatorial biosynthesis. Together, our findings provide a sound base for expanding the structure diversities of PoTeMs through genome mining and combinatorial biosynthesis

SBP1 had tumor suppressive functions.

<p>A, HCT116 cells transfected with HA-SBP1 had an increased sensitivity to H2O2 by MTS proliferation assay compared to the empty vector (HA). The cells were treated with H2O2 for 24 hours. B, HCT116 cells transfected with HA-SBP1 increased H2O2-induced apoptosis by Flow cytometry analysis. Cells were treated with 0.3 mM of H₂O₂ for 24 hours. Boxes indicate apoptotic cells (sub-G1). C, SBP1 inhibited cancer cell migration: cell migration of SBP1 overexpressing HCT116 cells and HA-control cells was assessed via transwell chambers. Migrated cells were detected with DAPI staining.</p